

# Reaping the rewards of a simplified dosing regimen

Peter E. Penson<sup>1,2</sup> and Maciej Banach<sup>2,3,4,5,\*</sup>

<sup>1</sup>Clinical Pharmacy & Therapeutics Research Group, School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK; <sup>2</sup>Liverpool Centre for Cardiovascular Science, Liverpool, UK; <sup>3</sup>Faculty of Medicine, The John Paul II Catholic University of Lublin, Lublin, Poland; <sup>4</sup>Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland; and <sup>5</sup>Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Received 26 September 2024; accepted 30 September 2024

**Commentary on: Weisser, B., S. Wassmann, H. G. Predel, R. E. Schmieder, A. Gillessen, T. Wilke, J. Blettenberg, O. Randerath, A. Mevius, and M. Bohm (2024). “Effect of a single pill concept on clinical and pharmaco-economic outcomes in cardiovascular diseases.” *Eur Heart J Cardiovasc Pharmacother*; <https://doi.org/10.1093/pvae059>.**

The recent history of cardiovascular medicine has been an outstanding success. Ferrari and Luscher have described how the reduction of cardiovascular disease (CVD) risk with new drugs is responsible for extending average expectancy by 6 years out of a total of 8 years for all medical interventions.<sup>1</sup> This remarkable achievement has been enacted through the systematic identification of risk factors (hypertension, apo-B-containing lipoproteins, smoking, hyperglycaemia, obesity) and the rational design of therapeutics to target each, in addition to addressing suboptimal lifestyle factors.<sup>2</sup>

Such approaches are clearly effective—the best evidence collated from multiple trials of different agents demonstrates that each 5 mmHg reduction in systolic blood pressure reduces the risk of major cardiovascular events (MACE) by 10–20% in adults aged less than 85 years.<sup>3</sup> Similarly, each 1 mmol/L (40 mg/dL) reduction in low-density lipoprotein cholesterol (LDL-C) reduces risk of MACE by approximately one-quarter.<sup>4</sup> Nevertheless, such undoubted success is not without complications.

The multifactorial causes of CVD and their amelioration by multiple specific treatments can result in patients having a substantial medication burden. Moreover, looking at the ongoing trials with new drugs for residual CVD risk factors e.g. associated with lipoprotein(a) or inflammation, it seems the optimal approach to CVD risk factor might be even more a challenge.<sup>2</sup> The polypharmacy often results in poor adherence and persistence of therapy and, therefore, poor outcomes for patients. Such effects are amplified in a manner which is not always apparent to prescribers, owing to the unrecognized substantial prevalence of adults (without physical cause) who have an aversion to swallowing tablets and capsules.<sup>5</sup> Whilst patients can be taught to swallow tablets more effectively,<sup>5</sup> however increased consideration has been especially given in recent years to reducing pill burden via combination therapies [often called fixed-dose combinations (FDC) or single pill concept (SPC)]—dosage forms (typically tablets or capsules) that contain more than one active ingredient.

Whilst antihypertensive combination therapies have been available in some regions for many years, great interest in this field was provoked by the promotion, by Wald and Law in the early 2000s of the ‘polypill’ concept of a single dosage form containing multiple agents, which had been demonstrated to significantly reduce cardiovascular risk.<sup>6</sup> Initially, much of the focus of this approach was on combining tried-and-tested off-patent drugs to produce a cheap and effective formulation.<sup>7</sup> The approach has been recognized as having a great value, and the European Society of Cardiology (ESC) Guidelines for the management of hypertension recommend initial combination therapy using a fixed-dose combination approach.<sup>8</sup> The same approach of upfront lipid lowering combination therapy (preferably as FDC) was recommended by the International Lipid Expert Panel in 2021 for very high CVD risk patients,<sup>9</sup> and next in the ESC Acute Coronary Syndrome Guidelines 2023.<sup>10</sup> Currently, the novel lipid-lowering agent, bempedoic acid, is available in a fixed-dose combination with ezetimibe,<sup>11</sup> and other drugs under development will be available as FDC with ezetimibe from the beginning (e.g. obicetrapib).

In light of these developments, the article by Weisser *et al.* ‘Effect of a single pill concept on clinical and pharmaco-economic outcomes in cardiovascular diseases’<sup>12</sup> published in this issue of *European Heart Journal—Cardiovascular Pharmacotherapy* is a most welcome addition to the literature. The authors sought to test the hypothesis that a SPC is superior to a multi-pill concept (MPC) in reducing CVD events, all-cause death, and costs in CVD patients. The authors used anonymized medical claims data between 2012 and 2018 from a population of patients with hypertension, dyslipidaemia, and CVDs, who started drug therapy either as SPC or an identical drug regimen delivered as an MPC. In order to reduce the bias inherent in such an observational study, 1:1-Propensity Score Matching (PSM) was employed. They found that the SPC approach was associated with a lower risk of all-cause mortality [incidence rate ratio (IRR)=0.62; 95% CI 0.57–0.68;  $P < 0.001$ ], stroke [IRR = 0.77; 95% confidence interval (CI) 0.67–0.88;  $P < 0.001$ ], myocardial infarction (IRR = 0.76; 95% CI 0.63–0.90;  $P = 0.0016$ ), heart failure (IRR = 0.59; 95% CI 0.54–0.64;  $P < 0.001$ ), and a range of additional outcomes.<sup>12</sup> The authors also noticed that mean time to first events and time to death were also in favour of SPC. Importantly, what was many times raised as an argument against polypills, mean total costs were 4708€ for SPC

\* Corresponding author. Tel: +48422711124, Email: [maciej.banach@icjzmp.edu.pl](mailto:maciej.banach@icjzmp.edu.pl)

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

## Benefits and risks of SPC/FDC in cardiovascular diseases management

### Benefits:

- Reduced number of tablets taken by patients (reduced risk of polypharmacy)
- Improved adherence, persistence and compliance
- Better results and earlier therapeutical targets achievements
- Reduced risk of side effects (less risk of intolerance) and the risk of discontinuation
- Significant reduction of CVD and mortality outcomes
- Lower costs

### Risks:

- Inconsistent knowledge on upfront combination therapy with SPC in the existing guidelines or lack of such recommendations
- Lack of experience of physicians with SPC (learning curve)
- Insufficient patients' knowledge on the role of combination therapy with SPC (critical role of patient educators and patient organizations)
- Large country to country differences in the availability of some FDC for CVD.
- Large country to country differences on indications, physicians that are allowed to prescribe, and reimbursement/costs of FDC

**Figure 1** Benefits and risks of single pill combination/ fixed-dose combinations in cardiovascular diseases management.

vs. 5.669€ for MPC, respectively ( $P < 0.001$ ). The authors conclude that, therefore, the SPC approach should become the (gold) standard of care in the treatment of hypertension, dyslipidaemia, and the secondary prevention of CVD.<sup>12</sup>

Whilst these conclusions seem rational and in line with the findings of other studies, it is important to consider some limitations of the study. The study included a very heterogeneous population, and whilst it may be argued that this improves the external validity of the study, it may complicate the interpretations of some findings. Of particular note, in the propensity-matched population, approximately 95% of patients had hypertension, whereas less than half had hyperlipidaemia, which does not reflect the population data. Whilst any extent of lipid (LDL-C) lowering appears to be effective, with no lower limit observed in studies,<sup>13,14</sup> whereas excessive blood pressure lowering may result in adverse effects. Therefore, an analysis of this type with a majority of hypertension patients may in fact underestimate the potential benefit which could be achieved in a population whose cardiovascular risk was driven to a greater extent by dyslipidaemia. Furthermore, the study necessarily treats all types of fixed-dose combinations equally in the analysis when they vary substantially in their composition and the effectiveness of the drugs included within them for the deduction of cardiovascular events. As with any observational study, residual confounding cannot be entirely eliminated, even after PSM, and it is important to note that the choice of treatments given to patients will have been made on clinical grounds in each case, potentially allowing for confounding by indication. Finally, it is also notable that the data in this study stopped in 2018. Since then, access and availability e.g. of injectable therapies for LDL-lowering (such as inclisiran<sup>15</sup> and monoclonal antibody PCSK9 inhibitors<sup>16</sup>) afford us new opportunities to improve the long-term management of cardiovascular risk factors even without the need for daily tablets.

Despite these limitations, the paper nevertheless adds to the body of knowledge already available from randomised controlled trials.

By including a large number of patients (approximately 50 000) and following up over years, the study has sufficient statistical power to evaluate the effect of fixed-dose combination therapy on mortality outcomes—and the findings appear to be very promising. It is always reassuring when hard clinical data support common-sense clinical practice, and based on these data, it does indeed seem that fixed-dose combination therapy can improve compliance and, crucially, outcomes for patients at risk of CVD, and should be recommended in all guidelines for CVD management (Figure 1).

**Conflict of interest:** P.E.P. owns four shares in AstraZeneca PLC and has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp, and Sanofi. M.B. has received research grant(s)/support from Amgen, Daiichi Sankyo, Mylan/Viatris, and Sanofi, and has served as a speaker and consultant for Adamed, Amgen, Daiichi Sankyo, Esperion, Exceed Pharma, Kogen, KRKA, Menarini, Mylan, Novartis, Novo Nordisk, Pfizer, Polpharma, Sanofi, Servier, Teva, and Zentiva.

### Data availability

No new data were generated or analysed in support of this research.

### References

1. Ferrari R, Lüscher TF. Reincarnated medicines: using out-dated drugs for novel indications. *Eur Heart J* 2016;**37**:2571–2576.
2. Makover ME, Surma S, Banach M, Toth PP. Eliminating atherosclerotic cardiovascular disease residual risk. *Eur Heart J* 2023;**44**:4731–4733.
3. Blood Pressure Lowering Treatment Trialists Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. *Lancet* 2021;**398**:1053–1064.
4. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, Van De Sluis B, Taskiran M-R, Tokgözoğlu L,

- Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J* 2017;**38**:2459–2472.
5. McCloskey AP, Penson PE, Tse Y, Abdelhafiz MA, Ahmed SN, Lim EJ. Identifying and addressing pill aversion in adults without physiological-related dysphagia: a narrative review. *Br J Clin Pharmacol* 2022;**88**:5128–5148.
  6. Wald NJ. A strategy to reduce cardiovascular disease by more than 80%. *BMJ* 2003;**326**:1419.
  7. Franczyk B, Gluba-Brzózka A, Jurkiewicz Ł, Penson P, Banach M, Rysz J. Embracing the poly-pill as a cardiovascular therapeutic: is this the best strategy? *Expert Opin Pharmacother* 2018;**19**:1857–1865.
  8. Mcevoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, Daskalopoulou SS, Ferro CJ, Gerds E, Hanssen H, Harris J, Lauder L, Mcmanus RJ, Molloy GJ, Rahimi K, Regitz-Zagrosek V, Rossi GP, Sandset EC, Scheenaerts B, Staessen JA, Uchmanowicz I, Volterrani M, Touyz RM, Abreu A, Olsen MH, Ambrosetti M, Androulakis E, Bang LE, Bech JN, Borger MA, Boutouyrie P, Bronze L, Buccheri S, Dalmou R, De Pablo Zarzosa MC, Delles C, Fiuza MM, Gabulova R, Haugen BO, Heiss C, Ibanez B, James S, Kapil V, Kayikcioglu M, Køber L, Koskinas KC, Locati ET, Macdonald S, Mihailidou AS, Mihaylova B, Mindham R, Mortensen MB, Nardai S, Neubeck L, Nielsen JC, Nilsson PM, Pasquet AA, Pedro MM, Prescott E, Rakisheva A, Rietzschel E, Rocca B, Rossello X, Schmid J-P, Shantsila E, Sudano I, Timóteo AT, Tsiogoulis G, Ungar A, Vaartjes I, Visseren F, Voeller H, Vrints C, Witkowski A, Zennaro M-C, Zeppenfeld K, Shuka N, Laredj N, Pavo N, Mirzoyev U, Van De Borne P, Sokolović Š, Postadzhiyan A, Samardžić J, Agathangelou P, Widimsky J, Olsen MH, El-Kilany WM, Pauklin P, Laukkanen JA, Boulestreau R, Tsinamdzgvrishvili B, Kintscher U, Marketou M, Páll D, Hrafnkelsdóttir Þj, Dolan E, Wolak T, Bilo G, Tundubayeva MK, Mirrakhimov E, Trusinskis K, Kiwan G, Msaalem O, Badariceni J, Banu C-A, Balbi MM, Caraus A, Boskovic A, Mouine N, Vromen T, Bosevski M, Midtbø HB, Doroszko A, Dores H, Badila E, Bini R, Simić DV, Fras Z, Mazón P, Spaak J, Burkard T, Barakat E, Abdessalem S, Gunes Y, Sirenko YM, Brady AJB, Khamidullaeva GA, Prescott E, James S, Arbello E, Baigent C, Borger MA, Buccheri S, Ibanez B, Køber L, Koskinas KC, Mcevoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Pasquet AA, Rakisheva A, Rocca B, Rossello X, Vaartjes I, Vrints C, Witkowski A, Zeppenfeld K. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. *Eur Heart J* 2024;**45**:3912–4018.
  9. Banach M, Penson PE, Vrablik M, Bunc M, Dyrbus K, Fedacko J, Gaita D, Gierlotka M, Jarai Z, Magda SL, Margetic E, Margoczy R, Durak-Nalbantica A, Ostadal P, Pella D, Trbusic M, Udroui CA, Vlachopoulos C, Vulic D, Fras Z, Dudek D, Reiner Ž. ACS EuroPath Central & South European Countries Project. Optimal use of lipid-lowering therapy after acute coronary syndromes: a position paper endorsed by the International Lipid Expert Panel (ILEP). *Pharmacol Res* 2021;**166**: 105499.
  10. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan G-A, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, Jüni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B, Halvorsen S, James S, Abdelhamid M, Aboyans V, Marsan NA, Antoniou S, Asteggiano R, Bäck M, Capodanno D, Casado-Arroyo R, Cassese S, Čelutkienė J, Cikes M, Collet J-P, Ducrocq G, Falk V, Fauchier L, Geisler T, Gorog DA, Holmvang L, Jaarsma T, Jones HW, Køber L, Koskinas KC, Kotecha D, Krychtiuk KA, Landmesser U, Lazaros G, Lewis BS, Lindahl B, Linhart A, Löchen M-L, Mamas MA, Mcevoy JW, Mihaylova B, Mindham R, Mueller C, Neubeck L, Niebauer J, Nielsen JC, Niessner A, Paradies V, Pasquet AA, Petersen SE, Prescott E, Rakisheva A, Rocca B, Rosano GMC, Sade LE, Schiele F, Siller-Matula JM, Sticherling C, Storey RF, Thielmann M, Vrints C, Windecker S, Wiseth R, Witkowski A, El Amine Bouzid M, Hayrapetyan H, Metzler B, Lancellotti P, Bajrić M, Karamfiloff K, Mitsis A, Ostadal P, Sorensen R, Elwasify T, Marandi T, Ryödi E, Collet J-P, Chukhrukidze A, Mehili J, Davlouros P, Becker D, Guðmundsdóttir IJ, Crowley J, Abramowitz Y, Indolfi C, Sakhov O, Elezi S, Beishenkulov M, Erglis A, Moussallem N, Benlamin H, Dobiliene O, Degrell P, Balbi MM, Grosu A, Lakhal Z, Ten Berg J, Pejkov H, Angel K, Witkowski A, De Sousa Almeida M, Chioncel O, Bertelli L, Stojkovic S, Studenčan M, Radšel P, Ferreiro JL, Ravn-Fischer A, Räber L, Marjeh MYB, Hassine M, Yildirim A, Parkhomenko A, Banning AP, Prescott E, James S, Arbello E, Baigent C, Borger MA, Buccheri S, Ibanez B, Køber L, Koskinas KC, Mcevoy JW, Mihaylova B, Mindham R, Neubeck L, Nielsen JC, Pasquet AA, Rakisheva A, Rocca B, Rossello X, Vaartjes I, Vrints C, Witkowski A, Zeppenfeld K, ESC Scientific Document Group. 2023 ESC guidelines for the management of acute coronary syndromes. *Eur Heart J* 2023;**44**:3720–3826.
  11. Banach M, Penson PE, Farnier M, Fras Z, Latkovskis G, Laufs U, Paneni F, Parini P, Pirro M, Reiner Ž, Vrablik M, Escobar C. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). *Prog Cardiovasc Dis* 2023;**79**:2–11.
  12. Weisser B, Wassmann S, Predel H-G, Schmieler RE, Gillessen A, Wilke T, Blettenberg J, Randerath O, Mevius A, Böhm M. Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases. *Eur Heart J Cardiovasc Pharmacother* 2024; <https://doi.org/10.1093/ehjcvp/pvae059>
  13. Cybulska B, Klosiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. *Prog Cardiovasc Dis* 2021;**67**:65–74.
  14. Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer—even at low risk. *BMC Med* 2020;**18**:320.
  15. Dyrbus K, Gašior M, Penson P, Ray KK, Banach M. Inclisiran—new hope in the management of lipid disorders? *J Clin Lipidol* 2020;**14**:16–27.
  16. Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? *Cardiovasc Res* 2019;**115**:e26–e31.